aTyr Pharma reports Q1 cash of $78.8M; Phase 3 sarcoidosis data on track for Q3 2025

aTYR PHARMA INC

Cash, restricted cash and investments at $78.8M as of March 31, 2025; cash runway sufficient for one year after Phase 3 readout.
Phase 3 EFZO-FIT top-line data (efzofitimod in pulmonary sarcoidosis) expected in Q3 2025; 268 patients enrolled at 85 sites.
Phase 2 EFZO-CONNECT (SSc-ILD) interim data on skin assessments expected in Q2 2025; up to 25 patients.
Appointed Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise; 25+ years industry experience.
R&D expenses $11.8M and G&A $4.0M in Q1 2025; preclinical ATYR2810 data presented at AACR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.